{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:52:53Z","timestamp":1791294773051,"version":"4.1.0"},"reference-count":47,"publisher":"Impact Journals, LLC","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,12,29]]},"DOI":"10.18632\/oncotarget.6082","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T14:40:53Z","timestamp":1447339253000},"page":"44551-44562","source":"Crossref","is-referenced-by-count":36,"title":["Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer"],"prefix":"10.18632","volume":"6","author":[{"given":"Kim","family":"Moran-Jones","sequence":"first","affiliation":[{"name":"Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia"},{"name":"St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Gloss","sequence":"additional","affiliation":[{"name":"Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia"},{"name":"St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajmohan","family":"Murali","sequence":"additional","affiliation":[{"name":"Department of Pathology and The Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Chang","sequence":"additional","affiliation":[{"name":"Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Colvin","sequence":"additional","affiliation":[{"name":"Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D.","family":"Jones","sequence":"additional","affiliation":[{"name":"Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Yuen","sequence":"additional","affiliation":[{"name":"Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viive M.","family":"Howell","sequence":"additional","affiliation":[{"name":"Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Brown","sequence":"additional","affiliation":[{"name":"Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol W.","family":"Wong","sequence":"additional","affiliation":[{"name":"FibroGen Inc., San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Spong","sequence":"additional","affiliation":[{"name":"FibroGen Inc., San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Scarlett","sequence":"additional","affiliation":[{"name":"Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia"},{"name":"School of Environmental & Life Sciences, University of Newcastle, Ourimbah, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neville F.","family":"Hacker","sequence":"additional","affiliation":[{"name":"School of Women's and Children's Health, University of New South Wales, and Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Laboratory of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel C.","family":"Mok","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goli","family":"Samimi","sequence":"additional","affiliation":[{"name":"Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia"},{"name":"St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,11,11]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Jemal","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"TCGA","year":"2011","journal-title":"Nature"},{"key":"4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Kurman","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"5","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Kurman","year":"2004","journal-title":"Am J Pathol"},{"key":"6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"Davidson","year":"1996","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0303-7207(01)00436-1","article-title":"Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells","volume":"175","author":"Skinner","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ccr.2005.05.024","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"7","author":"Joyce","year":"2005","journal-title":"Cancer Cell"},{"key":"10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1999.5552","article-title":"Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer","volume":"75","author":"Ringuette","year":"1999","journal-title":"Gynecol Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1095\/biolreprod62.6.1600","article-title":"Expression and action of kit ligand\/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer","volume":"62","author":"Skinner","year":"2000","journal-title":"Biol Reprod"},{"key":"12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1095\/biolreprod63.3.789","article-title":"Expression and action of transforming growth factor alpha in normal ovarian surface epithelium and ovarian cancer","volume":"63","author":"Skinner","year":"2000","journal-title":"Biol Reprod"},{"key":"13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0303-7207(01)00584-6","article-title":"Expression and action of transforming growth factor beta (TGFbeta1, TGFbeta2, TGFbeta3) in normal bovine ovarian surface epithelium and implications for human ovarian cancer","volume":"182","author":"Skinner","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1095\/biolreprod62.3.491","article-title":"Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer","volume":"62","author":"Skinner","year":"2000","journal-title":"Biol Reprod"},{"key":"15","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Gertig","year":"2008","journal-title":"Clin Cancer Res"},{"key":"16","first-page":"846387","article-title":"Molecular profiling predicts the existence of two functionally distinct classes of ovarian cancer stroma","volume":"2013","author":"McDonald","year":"2013","journal-title":"Biomed Res Int"},{"key":"17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000101323","article-title":"The role of tubular epithelial-mesenchymal transition in progressive kidney disease","volume":"185","author":"Thomas","year":"2007","journal-title":"Cells Tissues Organs"},{"key":"18","doi-asserted-by":"crossref","first-page":"F707","DOI":"10.1152\/ajprenal.00007.2002","article-title":"TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells","volume":"283","author":"Trojanowska","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1042\/BJ20051106","article-title":"The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells","volume":"393","author":"Dockrell","year":"2006","journal-title":"Biochem J"},{"key":"20","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.biocel.2008.07.025","article-title":"Functions and mechanisms of action of CCN matricellular proteins","volume":"41","author":"Lau","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/joe.0.1780169","article-title":"The CCN family: a new stimulus package","volume":"178","author":"Brigstock","year":"2003","journal-title":"J Endocrinol"},{"key":"22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0140-6736(03)15172-0","article-title":"CCN proteins: multifunctional signalling regulators","volume":"363","author":"Perbal","year":"2004","journal-title":"Lancet"},{"key":"23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s00268-001-0242-x","article-title":"Connective tissue growth factor gene expression alters tumor progression in esophageal cancer","volume":"26","author":"Buchler","year":"2002","journal-title":"World J Surg"},{"key":"24","first-page":"8917","article-title":"Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features","volume":"61","author":"Koeffler","year":"2001","journal-title":"Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"8887","DOI":"10.1158\/0008-5472.CAN-05-1702","article-title":"Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis","volume":"65","author":"Rowley","year":"2005","journal-title":"Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/1535-7163.MCT-05-0516","article-title":"Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer","volume":"5","author":"Korc","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"27","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1158\/0008-5472.CAN-06-0081","article-title":"Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis","volume":"66","author":"Longaker","year":"2006","journal-title":"Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"12325","DOI":"10.1073\/pnas.1300415110","article-title":"CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer","volume":"110","author":"Tuveson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"29","first-page":"7735","article-title":"Safety and Tolerability of Human Monoclonal Antibody FG-3019, Anti-Connective Tissue Growth Factor, in Patients with Idiopathic Pulmonary Fibrosis","volume":"26","author":"Raghu","year":"2004","journal-title":"Chest"},{"key":"30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccr.2009.10.018","article-title":"A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2","volume":"16","author":"Barrett","year":"2009","journal-title":"Cancer Cell"},{"key":"31","first-page":"255","article-title":"Ovarian surface epithelium: biology, endocrinology, and pathology","volume":"22","author":"Leung","year":"2001","journal-title":"Endocr Rev"},{"key":"32","doi-asserted-by":"crossref","first-page":"10813","DOI":"10.1158\/0008-5472.CAN-07-0172","article-title":"Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination","volume":"67","author":"Ramakrishnan","year":"2007","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"F721","DOI":"10.1152\/ajprenal.00368.2009","article-title":"Connective tissue growth factor (CTGF\/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate","volume":"298","author":"Matsuo","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"34","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/gut.2005.079178","article-title":"A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2\/CTGF) promotes adhesion and migration of activated pancreatic stellate cells","volume":"55","author":"Brigstock","year":"2006","journal-title":"Gut"},{"key":"35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/gyno.1999.5388","article-title":"Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium","volume":"73","author":"Cannistra","year":"1999","journal-title":"Gynecol Oncol"},{"key":"36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/35077241","article-title":"The microenvironment of the tumour-host interface","volume":"411","author":"Kohn","year":"2001","journal-title":"Nature"},{"key":"37","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1158\/1078-0432.CCR-05-0231","article-title":"Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells","volume":"11","author":"Koeffler","year":"2005","journal-title":"Clin Cancer Res"},{"key":"38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/PGP.0b013e31824d1891","article-title":"Inverse expression of cystein-rich 61 (Cyr61\/CCN1) and connective tissue growth factor (CTGF\/CCN2) in borderline tumors and carcinomas of the ovary","volume":"31","author":"Hauptmann","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"39","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/carcin\/bgr140","article-title":"Modelling genetic and clinical heterogeneity in epithelial ovarian cancers","volume":"32","author":"Gayther","year":"2011","journal-title":"Carcinogenesis"},{"key":"40","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ijc.24347","article-title":"Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion","volume":"125","author":"Stack","year":"2009","journal-title":"Int J Cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ijc.24188","article-title":"Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype","volume":"124","author":"Brown","year":"2009","journal-title":"Int J Cancer"},{"key":"42","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1158\/0008-5472.CAN-06-4567","article-title":"Promoter Hypermethylation Contributes to Frequent Inactivation of a Putative Conditional Tumor Suppressor Gene Connective Tissue Growth Factor in Ovarian Cancer","volume":"67","author":"Imoto","year":"2007","journal-title":"Cancer Res"},{"key":"43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.celrep.2013.07.010","article-title":"Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer","volume":"4","author":"Han","year":"2013","journal-title":"Cell Rep"},{"key":"44","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.1158\/0008-5472.CAN-05-2240","article-title":"Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary","volume":"65","author":"Gershenson","year":"2005","journal-title":"Cancer Res"},{"key":"45","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1078-0432.CCR-12-2736","article-title":"Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer","volume":"19","author":"Mok","year":"2013","journal-title":"Clin Cancer Res"},{"key":"46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3835(94)90031-0","article-title":"A novelmethod for assaying adhesion of cancer cells to the peritoneum","volume":"78","author":"Nagamachi","year":"1994","journal-title":"Cancer Lett"},{"key":"47","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/1055-9965.EPI-11-0917","article-title":"TLE3 Expression Is Associated with Sensitivity to Taxane Treatment in Ovarian Carcinoma","volume":"21","author":"Huh","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T14:23:44Z","timestamp":1589379824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,11]]},"references-count":47,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2015,12,29]]}},"alternative-id":["6082","26575166"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.6082","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,11]]}}}